Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
Top Cited Papers
Open Access
- 24 July 2009
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 21 (2), 325-330
- https://doi.org/10.1093/annonc/mdp329
Abstract
Background: There are few data on the incidence and prognosis of extramedullary (EM) multiple myeloma (MM). There are concerns about a possible increase of EM relapses with the expanding use of high-dose therapy (HDT) and biological agents. Patients and methods: The incidence of EM disease, its relationship with prior exposure to HDT or novel agents, and its prognostic impact were analyzed in 1003 MM patients. Based on the different therapies available, three periods were considered: 1971–1993, conventional-dose chemotherapy; 1994–1999, HDT for younger patients; and 2000–2007, introduction of novel agents. Results: Overall, 13% of patients had EM disease, 7% at diagnosis and 6% later. In the 2000–2007 period, there was a significant increase of EM involvement, at diagnosis (P = 0.02) and during follow-up (P = 0.03). The risk of EM spread was not significantly increased after HDT [hazard ratio (HR 0.6)], bortezomib (HR 1.62), or thalidomide/lenalidomide (HR 1.07). EM disease was associated with shorter overall (HR 3.26, P < 0.0001) and progression-free (HR 1.46, P = 0.04) survival. Conclusions: The incidence of EM disease has increased, probably due to the availability of more sensitive imaging techniques and the prolongation of patients’ survival. HDT or novel agents seem not to increase the risk of EM disease. EM involvement confers a poor prognosis.Keywords
This publication has 35 references indexed in Scilit:
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003Journal of Clinical Oncology, 2007
- Plasmacytoma relapses in the absence of systemic progression post‐high‐dose therapy for multiple myelomaEuropean Journal of Haematology, 2005
- Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single centerEuropean Journal of Haematology, 2004
- Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcomeBone Marrow Transplantation, 2004
- Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remissionBone Marrow Transplantation, 2003
- Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancyBone Marrow Transplantation, 2000
- Late and localized extramedullary relapse of a light chain kappa myeloma after syngeneic bone marrow transplantationBone Marrow Transplantation, 2000
- Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 YearsBritish Journal of Haematology, 1996
- Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases.Journal of Clinical Oncology, 1994